ATE238427T1 - Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie - Google Patents

Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie

Info

Publication number
ATE238427T1
ATE238427T1 AT96907398T AT96907398T ATE238427T1 AT E238427 T1 ATE238427 T1 AT E238427T1 AT 96907398 T AT96907398 T AT 96907398T AT 96907398 T AT96907398 T AT 96907398T AT E238427 T1 ATE238427 T1 AT E238427T1
Authority
AT
Austria
Prior art keywords
vectors
relates
present
antimicrobial peptides
gene therapy
Prior art date
Application number
AT96907398T
Other languages
English (en)
Inventor
Walter H Guenzburg
David Winder
Robert Michael Saller
Original Assignee
Austrian Nordic Biotherapeutic
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austrian Nordic Biotherapeutic, Gsf Forschungszentrum Umwelt filed Critical Austrian Nordic Biotherapeutic
Application granted granted Critical
Publication of ATE238427T1 publication Critical patent/ATE238427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96907398T 1995-03-09 1996-03-08 Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie ATE238427T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK24395 1995-03-09
PCT/EP1996/001001 WO1996028563A1 (en) 1995-03-09 1996-03-08 Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy

Publications (1)

Publication Number Publication Date
ATE238427T1 true ATE238427T1 (de) 2003-05-15

Family

ID=8091353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96907398T ATE238427T1 (de) 1995-03-09 1996-03-08 Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie

Country Status (10)

Country Link
US (1) US7022319B1 (de)
EP (1) EP0817858B1 (de)
JP (1) JP3908274B2 (de)
AT (1) ATE238427T1 (de)
AU (1) AU5103996A (de)
DE (1) DE69627644T2 (de)
DK (1) DK0817858T3 (de)
ES (1) ES2198479T3 (de)
PT (1) PT817858E (de)
WO (1) WO1996028563A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198210C (en) * 1994-09-02 2006-07-11 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Non self-inactivating, expression targeted retroviral vectors
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
ATE298371T1 (de) 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
GB2344592B (en) * 1997-09-25 2002-09-11 Oxford Biomedica Ltd Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
EP1045922B1 (de) 1998-01-06 2004-09-29 Institut für Virologie Teilrechtsfähiges Institut an der Veterinärmedizinischen Universität Wien Rekonstituierender retroviraler vektor (recon vektor) für gezielte genexpression
GB9817693D0 (en) * 1998-08-14 1998-10-07 Bridgehead Technologies Limite Virally-mediated targeting of drugs and genetic material
DE19910650A1 (de) * 1999-03-10 2000-09-21 Gsf Forschungszentrum Umwelt Auf HERV-LTR-Sequenzen basierende retrovirale Expressionsvektoren
GB9906615D0 (en) * 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
WO2008154644A1 (en) * 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
EP2454276A4 (de) * 2008-07-17 2013-07-10 Inter K Pty Ltd Therapeutika

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US4822608A (en) 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
US5658775A (en) * 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
WO1989011539A1 (en) 1988-05-17 1989-11-30 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DK0504191T3 (da) * 1989-12-07 1995-03-27 Gsf Forschungszentrum F Præparat til behandling af HIV-infektioner
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
EP0668781B1 (de) * 1991-10-25 1999-12-29 Sidney Kimmel Cancer Center Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
WO1995000178A1 (en) 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
AU7321294A (en) * 1993-06-30 1995-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Transformed eukaryotic cells, and transposon-based transformation vectors
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
CA2198210C (en) * 1994-09-02 2006-07-11 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Non self-inactivating, expression targeted retroviral vectors
JPH11508441A (ja) 1995-03-09 1999-07-27 ババリアン・ノルディック・リサーチ・インスティテュート・アクティーゼルスカブ 遺伝子治療用の新規組換えdnaベクター
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
DK0848757T3 (da) 1995-09-06 2002-07-01 Austrian Nordic Biotherapeutic Anvendelse af WAP eller MMTV regulatoriske sekvenser for målrettet ekspression af sammenkædede heterologe gener i humane mammae celler, inklusiv humane mammae carcinoma celler
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
EP1025208A2 (de) 1997-10-20 2000-08-09 Universita' Degli Studi Di Padova Verpackungszellinie zur herstellung von pseudotypisiertem mlv
EP1045922B1 (de) 1998-01-06 2004-09-29 Institut für Virologie Teilrechtsfähiges Institut an der Veterinärmedizinischen Universität Wien Rekonstituierender retroviraler vektor (recon vektor) für gezielte genexpression

Also Published As

Publication number Publication date
ES2198479T3 (es) 2004-02-01
DE69627644D1 (de) 2003-05-28
WO1996028563A1 (en) 1996-09-19
JPH11503305A (ja) 1999-03-26
DE69627644T2 (de) 2004-02-19
US7022319B1 (en) 2006-04-04
AU5103996A (en) 1996-10-02
JP3908274B2 (ja) 2007-04-25
EP0817858B1 (de) 2003-04-23
DK0817858T3 (da) 2003-08-11
PT817858E (pt) 2003-09-30
EP0817858A1 (de) 1998-01-14

Similar Documents

Publication Publication Date Title
AU555293B2 (en) Hybrid human leukocyte interferons
DE69627644D1 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
AU596997C (en) Pharmaceutical composition for the treatment of leukopenia
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
NZ320889A (en) A p35 protein which binds to and inhibits chemokines
EP1401477A4 (de) Chemokin-beta-1-fusionsproteine
EP0845530A3 (de) Interferon gamma induzierender Faktor
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
MY167485A (en) Recombinant human interferon-like proteins
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
WO2003016472A3 (en) Hybrid interferon/interferon tau proteins, compositions and methods of use
MY198257A (en) Gene Therapy With Dysferlin Dual Vectors
WO2023096996A3 (en) Chimeric hsv expressing hil21 to boost anti-tumor immune activity
ATE234929T1 (de) Vektor zur expression von therapeutisch relevanten genen
HUP0104598A1 (hu) Hepatocita-eredetű növekedési faktorból (HGF) és makrofágstimuláló proteinből (MSP) származó rekombináns proteinek
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0817858

Country of ref document: EP